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cAMPFor many G protein-coupled receptors (GPCRs), the role of the ﬁrst intracellular loop (IL1) and its connections
with adjacent transmembrane (TM) regions have not been investigated. Notably, these regions harbor several
polar residues such as Ser and Thr. To begin uncovering how these polar residuesmay contribute to the structural
basis for GPCR functionality, we have designed humanD1-class receptormutants (hD1-ST1 and hD5-ST1) where-
by all Ser and Thr of IL1 and IL1/TM2 juncture have been replaced by Ala and Val, respectively. Both ST1mutants
exhibited a loss of dopamine afﬁnity but similar binding properties for inverse agonists compared to their parent
receptors. As well, these mutations diminished receptor activation for both subtypes, as indicated by an ablated
constitutive activity and a pronounced decrease in dopamine potency. Interestingly, both mutants exhibited en-
hanced dopamine-mediated maximal stimulation (Emax) of adenylyl cyclase that was at least two-fold higher
than wild-type. Point mutations for hD1R revealed that the loss in dopamine afﬁnity and potency was attributed
to Thr59, while the enhanced Emax of adenylyl cyclase was directly inﬂuenced by Ser65. These two residues are
conserved amongmany FamilyAGPCRs andhave recurringmolecular interactions among crystallized structures.
As such, their functional roles for IL1 and its transition into TM2 reported herein may also be applicable to other
GPCRs. Our work thus potentially highlights a structural role of Thr59 and Ser65 in the formation of critical intra-
molecular interactions for ligand binding and signal transduction of D1-class dopaminergic receptors.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Dopamine receptors are G protein-coupled receptors (GPCRs) that
modulate diverse physiological functions in the central nervous system
such as motor control, learning, and emotion [1]. They can be grouped
into two families, D1-class and D2-class, primarily based on comparable
biochemical and structural properties. The D1-class, consisting of D1 and
D5 subtype receptors, couple to Gs/olf to stimulate adenylyl cyclase (AC)
activity and to increase intracellular cAMP levels [2]. In addition, D1 and
D5 receptors share over 80% amino acid sequence identity within their
transmembrane (TM) helices [2]. Yet, when expressed in various mam-
malian cell lines, the two subtypes display distinguishing pharmacolog-
ical properties. D5 receptors not only stimulate a higher AC activity in
the absence of agonists but also an increased afﬁnity and potency foreuroscience, 451 Smyth Road,
. This is an open access article underagonists compared to D1 receptors [2]. Therefore, the relationship
between D1 and D5 receptors can be viewed as analogous to the
relationship between wild-type and constitutively active mutant
forms of GPCRs [2,3]. In physiological and clinical settings, compromised
D1 and D5 receptor activities can be pertinent for blood pressure main-
tenance [4,5], cognitive performance [6,7], and be a contributing factor
towards neurodegenerative diseases in the brain [8,9]. Understanding
the mechanisms of D1-class receptor function is thus a prerequisite for
developing novel drugs and improved therapeutic strategies to treat
diseases in the future.
While studies exploring the structural basis for subtype-speciﬁc
pharmacological properties among D1-class receptors have strongly
implicated a role for the third intracellular loop (IL3) and cytoplasmic
tail (CT) [2], the functional signiﬁcance of other regions such as the
ﬁrst intracellular loop (IL1) is presently unknown. The IL1 region,
even among other GPCRs, has not been extensively studied, and conse-
quently, our understanding of its role in GPCR functionality requires
much development.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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can regulate receptor activation and G protein coupling [10–16]. For
instance, it has been demonstrated that mutating either a Leu or a Ser
residue in IL1 of gonadotropin-releasing hormone receptor diminished
its agonist-induced cAMP responses [17]. These residues reside within
a BBXXB motif (where B corresponds to a basic amino acid and X indi-
cates any residue) that is usually found on the second intracellular
loop (IL2), IL3, and CT domains and hypothesized to be a recognition
site by G proteins [18,19]. For the bradykinin B2 receptor, a Glu residue
within its IL1 was predicted to form electrostatic interactions with pos-
itively charged residues [14]. Its mutation led to decreased bradykininFig. 1. Ser and Thr residues of IR1 for human D1-class receptors and other Family A GPCRs. (A)
hD5R are identiﬁedwithﬁlled black circles. Residues composing the IR1 (Ala47–Ser65 inhD1R an
tical residues betweenhD1R and hD5R) and open gray circles. Boundaries and Ser/Thr residues o
ber. (B) Sequence alignment of the IR1 of humanD1-class receptors (highlighted in rectangle) sh
in many human Family A GPCRs. Ser and Thr within this region are shown in red. For simplici
these conserved Ser and Thr are denoted as Thr2.39 and Ser2.45 relative to the conserved Asp
ac.uk/Tools/msa/clustalo/).binding and subsequent decreases in bradykinin-stimulated inositol
phosphate production (Gq coupled pathway) and arachidonic acid
release (Gi coupled pathway). Furthermore, selective mutations of His
or Arg in IL1 of the thyroid-stimulating hormone receptor (TSHR)
caused impairments to its Gq-mediated signaling [15]. These two resi-
dues were shown to directly interact with the heterotrimeric Gq protein
in a homology model of TSHR [15].
Investigations into IL1 have been difﬁcult, and thus limited, possibly
because of the harmful effects of IL1 mutations and deletions on recep-
tor expression. Indeed, previous works have revealed a role for IL1 in
receptor trafﬁcking. For example, a conserved Leu residue at the centerPlots of hD1R and hD5R illustrating TM1, IL1, and TM2. Identical residues among hD1R and
dAla64–Ser82 inhD5R) are indicatedwith red single letter aminoacid code inﬁlled (iden-
f IR1 for D1-class receptors are labeledwith their corresponding amino acid sequencenum-
ows Thr59 and Ser65 for hD1R and the analogous Thr76 and Ser82 for hD5R are conserved
ty and ease of comparison, the Ballesteros–Weinstein nomenclature [48] is used in which
2.50 (asterisk) in TM2. Sequence alignment was created using Clustal Omega (www.ebi.
2016 B. Zhang et al. / Cellular Signalling 27 (2015) 2014–2025of IL1 was necessary for endoplasmic reticulum (ER) export of
β2-adrenoceptors, α1b/α2b-adrenoceptors, and angiotensin II AT1
receptors [20]. Although the mechanistic underpinnings for this single
Leu residue have yet to be explained, it has been reported that an inter-
action between activated C-kinase 1 and IL1 of thromboxane A2 recep-
tor (TPβ) was required to transport TPβ from the ER to the cell surface
[21].
Collectively, this handful of studies illustrates the importance of
molecular interactions among IL1 residues and institute IL1 as a vital
cog within the GPCR machinery. In IL1 for D1-class receptors, residues
that can potentially fulﬁll a similar role include Ser/Thr residues due to
the hydrogen bonding capabilities of their hydroxyl side chains. As
Fig. 1A shows, within the 19 amino acid stretch spanning IL1 and the
junctures between TM1/IL1 and IL1/TM2 – herein referred to as
intracellular-oriented region 1 (IR1) – both human D1 and D5 receptors
(hD1R; hD5R) possess two Ser and one Thr. Ser56 and Ser68 of IR1 are
unique to hD1R and hD5R, respectively (Fig. 1A). The remaining two
(Thr59 and Ser65 in hD1R; Thr76 and Ser82 in hD5R) are not only
conserved between D1-class receptors but also conserved among
other human Family A GPCRs and therefore lends credence to our
hypothesis that Ser/Thr residues of IR1 are important for D1-class
receptor function (Fig. 1B). In the present study, we used a site-directed
mutagenesis approach to construct a series of mutant D1-class receptors
whereby all or individual Ser and Thr spanning IR1 were replaced by
Ala and Val, respectively. Our results reveal that Ser/Thr residues of IR1
are novel “hotspots” for D1-class receptor regulation because of their
diverse contributions including receptor expression, agonist binding,
constitutive activity, and dopamine-induced activation of AC. Further-
more, based on solved GPCR structures, Ser/Thr residues of IR1 may
participate in the formation of critical molecular motifs for GPCR
activation and signaling in general that have not been fully recognized
previously.
2. Material and methods
2.1. Materials
N-[methyl-3H]-SCH23390 and [3H]-adenine were purchased from
Perkin Elmer (Boston,MA, USA). [14C]-cAMPwas obtained fromMoravek
Biochemicals (Brea, CA, USA). Ascorbic acid, dopamine, cis-ﬂupenthixol,
thioridazine, thiothixene, and 1-methyl-3-isobutylxanthine (IBMX)Table 1
Primer sequences used to create untagged andHA-taggedmutant receptors of IR1. Nucleotides
Val or surrounded by round brackets when used to either introduce new or remove restriction
Receptor Primer sequences (5′→ 3′)
hD1-S56Aa P1: ccATggTgATgcggTTTT
P2: cAccTTgg[c]ccgcAggTgTc
P3: cTggTcTgTgcTgc(A)gTTA
P4: TTAggAcAAggcTggTgg
P5: cAAAATgTcgTAATAAcccc
P6: gcAAAgTcTgTAccATccTAA
hD1-T59Vb P1: ccATggTgATgcggTTTT
P2: cAAgAgATc(c)gAcAcAgcc
P3: cggTccAAggTg[gT]cAAcT
P4: TTAggAcAAggcTggTgg
P5: cAAAATgTcgTAATAAcccc
P6: gcAAAgTcTgTAccATccTAA
hD1-S65Ac P1: ccATggTgATgcggTTTT
P2: AgccAAgg[c]gATgAcAAA
P3: AcgcTggTcTgTgc(g)gccgT
P4: TTAggAcAAggcTggTgg
P5: cAAAATgTcgTAATAAcccc
P6: gcAAAgTcTgTAccATccTAA
HA-hD1-ST1 P1: gAATTcgccgccAccATgTAc
P2: gcAAAgTcTgTAccATccTAA
a Silent mutation added a PstI site.
b Silent mutation removed a BglII site.
c Silent mutation added a EagI site.were obtained fromSigma-Aldrich (Oakville, ON, Canada). Dihydrexidine
was from Tocris Bioscience (Ellisville, MO, USA). Minimal essential media
(MEM) and phosphate buffered-saline (PBS) were bought fromWisent
Bioproducts (St-Bruno, QC, Canada). Fetal bovine serum (FBS), trypsin,
HEPES buffer, and gentamicin were acquired from Life Technologies
(Burlington, ON, Canada). Paraformaldehydewas obtained from Electron
Microscopy Sciences (Hatﬁeld, PA, USA).
2.2. Construction of mutant receptors
Mutations of all Ser and Thr residues located in cytoplasmic regions
and intracellular-TM interfaces of hD1R and hD5Rweremade by custom
gene synthesis into pUC57 plasmid vector (GenScript USA Inc., NJ, USA).
The resulting custom made plasmid DNAs (cm-hD1R and cm-hD5R)
were used to generate hD1-ST1 and hD5-ST1 mutants as follows. An
EcoRI/BglII DNA cassette derived from cm-hD1R pUC57 construct
(~220 bp) was subcloned into hD1R pCMV5 expression plasmid DNA
linearized with EcoRI and BglII to give hD1-ST1 in pCMV5. To create
the hD5-ST1 pCMV5, the KpnI-HaeII (~290 bp) and HaeII-HindIII
(~1160 bp) obtained from cm-hD5R pUC57 construct were ligated to
empty pCMV5 vector digested with EcoRI and HindIII. Single point
mutants (S56A, T59V and S65A) of hD1R were constructed using the
polymerase chain reaction (PCR)-based overlap extension strategy
detailed previously [22]. In brief, primer pairs P1–P2 and P3–P4
(Table 1) ampliﬁed existing hD1R pCMV5 expression plasmid DNA
(EcoRI-XbaI) to generate two PCR fragments (i.e.megaprimers) contain-
ing targeted Ser-to-Ala/Thr-to-Val mutations and silent mutations. The
purpose of silent mutations was to create new restriction endonuclease
sites for diagnostic testing (Table 1). A second PCR step took advantage
of the overlapping region betweenmegaprimers to generate an overlap
product using primer pair P5–P6 (Table 1). Overlap products were then
double digestedwith EcoRI andHindIII and subcloned into hD1R pCMV5
expression construct linearized with EcoRI and HindIII. Tagging the
N-terminus of single point mutants with a human inﬂuenza hemagglu-
tinin epitope (HA: YPYDVPDYA) was implemented using the same
approach and primers, except existing HA-tagged hD1R expression
plasmid DNA [22] was used as template. HA tagging of the N-terminus
of hD1-ST1 was done using a single step PCR approach using P1 and
P2 primers (Table 1), and untagged hD1-ST1 pCMV5 expression plasmid
DNA as template. The resulting PCR product (~1250 bp) was double
digested with EcoRI and HindIII (~650 bp fragment) and subclonedaremarked in bold surrounded by square bracketswhen used tomutate Ser-to-Ala/Thr-to-
endonuclease sites.
ggAAccTgATAAc(T)gcAgcAcAgAccAgcgTgTTccc
TcAggTTccgAcAccTgcgg[g]ccAAggTgAccAAcTTc
g
gAgggT
AAggAgATgAcAAAgAAgTTg[Ac]cAccTTggAccgcAggTgTcg
TcTTTgTcATcTccTTggcTgTgTc(g)gATcTcTTggTggccgTc
g
gAgggT
gAAgTTggTcAccTTggAccgcAggTgTcggAAccTgATAAcggc (c)gcAcAgAccAgcgTgTTccccAg
TATcAggTTccgACAccTgcggTccAAggTgAccAAcTTcTTTgTcATc[g]ccTTggcTgTgTcAgAT
g
gAgggT
ccATAcgAcgTcccAgAcTAcgcTAggAcTcTgAAc
gAgggT
Table 2
Saturation and competition binding parameters for D1-class and ST1 mutant receptors.
pKD and pKI (negative logarithmofKD andKI inmolar units) and Bmax values are expressed asmeans±S.E. from4 to 8 separate experiments done induplicate. The correspondingKD andKI
values in nM are shown in brackets. Binding parameters measured with each ligand were analyzed using two-tailed unpaired t tests with a critical α= 0.05.
Saturation curves Competition curves
[3H]-SCH23390 (n = 6–8) Dopamine (n = 5–6) Dihydrexidine (n = 6–8) Thioridazine (n = 4–5) Thiothixene (n = 4–5)
pKD (KD, nM) Bmax (pmol/mg) pKI(KI, nM)
hD1R 9.35 ± 0.03 (0.45) 8.14 ± 0.90 5.09 ± 0.05 (8214) 6.27 ± 0.05 (544) 7.04 ± 0.03 (91.4) 7.17 ± 0.01 (68.2)
hD1-ST1 9.46 ± 0.07 (0.35) 1.22 ± 0.10⁎ 4.73 ± 0.04 (18,490)⁎ 6.30 ± 0.08 (506) 7.15 ± 0.08 (71.0) 7.39 ± 0.05 (41.1)⁎
hD5R 9.15 ± 0.05 (0.71) 16.2 ± 2.0 6.02 ± 0.03 (966) 7.08 ± 0.04 (83.5) 6.17 ± 0.02 (674) 6.24 ± 0.01 (576)
hD5-ST1 9.11 ± 0.08 (0.77) 0.79 ± 0.12# 5.45 ± 0.07 (3557)# 6.53 ± 0.09 (294)# 6.06 ± 0.1 (866) 6.19 ± 0.04 (649)
⁎ p b 0.05 when hD1-ST1 compared to hD1R.
# p b 0.05 when hD5-ST1 compared to hD5R.
2017B. Zhang et al. / Cellular Signalling 27 (2015) 2014–2025into untagged hD1-ST1 pCMV5 expression plasmid DNA linearized with
EcoRI and HindIII. To obtain HA-tagged hD5-ST1, the SmaI fragment
(~1600 bp) derived from hD5-ST1 pCMV5 expression plasmid DNA
was subcloned into hD5R pCMV5 expression plasmid DNA linearized
with SmaI. DNA sequences of engineered receptor constructs were
veriﬁed by automated DNA sequencing performed at StemCore Labora-
tories of the Ottawa Hospital Research Institute (Ottawa, ON, Canada,
www.stemcore.ca). Primers were custom-made at Sigma-Aldrich
(Oakville, ON, Canada).
2.3. Cell culture and transfection
Human embryonic kidney 293 (HEK293) cells (American Type
Culture Collection, Manassas, VA, USA; CRL-1573) were cultured inFig. 2. Impact of Ser/Thr mutations of IR1 on D1-class receptor expression. (A, B) Sample West
munoblotting studies were performed four times using 40 μg of cell lysate proteins for eachmo
of sampleWestern blots were: 15.2 (hD1R), 1.59 (hD1-ST1), 16.1 (hD5R), and 0.293 (hD5-ST1).
wild-type receptors. Each bar represents the mean ± S.E. from four experiments done in tripli
(pmol/mg of membrane proteins) for (C, D) expressed as means ± S.E., were: 10.6 ± 0.32 (H
0.24 ± 0.02 (HA-tagged hD5-ST1). All experiments (A–D) were performed using 5 μg of transfMEM containing heat-inactivated FBS (10% (v/v)) and gentamicin
(20 μg/ml) at 37 °C with humidiﬁed air and 5% CO2. Cell transfection
(2.5 × 106 cells/100-mm dish) was performed using a modiﬁed cal-
cium phosphate precipitation method described previously [22].
For saturation and competition studies, each dish was transfected
with 5 μg of receptor DNA to maximize the receptor expression
that we found is obtainable in HEK293 cells [22]. For constitutive activ-
ity and dose–response studies, lower amounts of wild-type andmutant
DNA constructs were used to obtain low tomoderate receptor levels. In
this case, empty pCMV5 vectorwas added to complete the total amount
of DNA to 5 μg per dish. Following transfection and overnight incuba-
tion, cells were washed with PBS, detached with trypsin, and reseeded
in appropriate dishes to be grown for an additional 48 h. HEK293 cells
from 41 to 52 passages were employed in studies.ern blots of hD1R and hD5R compared with their corresponding ST1 mutant receptor. Im-
ck and receptor condition. Bmax values (A, B) expressed as pmol/mg ofmembrane proteins
(C, D) Cell surface expressions, obtained by ELISA, of ST1 mutant receptors relative to their
cate. *, p b 0.05 using one-sample t test when compared to 100% (wild-type). Bmax values
A-tagged hD1R), 1.28 ± 0.10 (HA-tagged hD1-ST1), 14.6 ± 1.5 (HA-tagged hD5R), and
ected receptor or pCMV5 vector DNA only (Mock). h, human.
2018 B. Zhang et al. / Cellular Signalling 27 (2015) 2014–20252.4. Radioligand binding assay
Crude membranes were obtained from cells reseeded in 150-mm
dishes using the protocol described previously [22]. They were used
either immediately for saturation studies or frozen in liquid nitrogen
and stored in−80 °C to be employed for competition studies. Fresh or
frozen membranes (thawed on ice) were homogenized with
Brinkmann Polytron (17,000 rpm for 15 s) in resuspension buffer
(62.5 mM Tris–HCL, pH 7.4; 1.25 mM EDTA, pH 8.0). Saturation studies
were performed by adding 100 μl of membrane into a mixture with a
total volume of 500 μl that contained (ﬁnal concentration in assays):
binding buffer (50 mM Tris–HCL, pH 7.4; 120 mM NaCl; 5 mM KCL;
4 mM MgCl2; 1.5 mM CaCl2; 1 mM EDTA, pH 8.0), water or 10 μM of
cis-ﬂupenthixol, and increasing concentrations of [3H]-SCH23390
(0.03 nM to 9 nM). Competition studies were performed using the
aforementioned amounts of membrane and binding buffer with a
constant concentration of [3H]-SCH23390 (0.5–1 nM) and increasing
concentrations of cold drug for a total volume of 500 μl. Dopamine
was dissolved in 0.1 mM ascorbic acid (ﬁnal assay concentration).
Dihydrexidine, thioridazine, and thiothixene were dissolved in water.
For saturation and competition studies, the mixture was allowed to
incubate at room temperature for 90min before undergoing rapidﬁltra-
tion through glass ﬁber ﬁlters (GF/C, Whatman). Cold buffer solution
(50 mM Tris–HCL, pH 7.4; 100 mM NaCl) was used to wash the ﬁlters
three times. Scintillation liquid from Bio-Safe II (Research Products
International Corp, Mount Prospect, IL, USA) was added to the ﬁlter
disks, and bound radioactivity was measured with a beta counter
(Beckman Counter, LS 6500). Protein concentrations of membraneFig. 3. Impact of Ser/Thr mutations of IR1 on agonist-independent and dependent stimulation o
relative to wild-type that is expressed as mean ± S.E. from three to ﬁve experiments done in tr
(hD1R), 1.77±0.38 (hD1-ST1), 0.40±0.13 (hD5R), and 0.37±0.10 (hD5-ST1). *,p b 0.05 using
mutant valueswere not statistically detectable (p N 0.05) using an unpaired t test (GraphPad Pri
with a four parameter logistic equation and sharedHill slope value using global nonlinear regres
each point in relation to the best-ﬁtted wild-type Emax value (set to 100%) and then plotting th
regression curve ﬁtting approach. Each point represents the mean ± S.E. from four to ﬁve exp
units) ± approximate S.E. and corresponding EC50 (in brackets) were: hD1R, 7.62 ± 0.16 (2
6.84±0.21 (144 nM). Best-ﬁtted values of Emax (%)± approximate S.E. were 100±4.8 (hD1R),
of ST1mutants were statistically different (p b 0.05) relative to their correspondingwild-type re
ﬁtting approach. Bmax values (pmol/mg of membrane proteins) in means ± S.E. were: 1.14 ±
human.preparations were determined using Bio-Rad Protein Dye Reagent
(Bio-Rad Laboratories Inc, Mississauga, ON, Canada) and bovine serum
albumin (BSA) as standard.
2.5. Whole-cell cAMP assay
Dishes containing 6-wells and 12-wells were used for cell reseeding
to assess basal and dopamine-mediated AC activation, respectively.
Once media was aspirated the following day, cells were metabolically
labeled with [3H]-adenine (1–2 μCi/ml) in MEM containing 5% (v/v)
FBS and gentamicin (20 μg/ml) overnight. This media was aspirated
the next day, and cells were supplemented with MEM containing
20 mM HEPES and 1 mM IBMX. Cells were treated with either 0.1 mM
ascorbic acid (ﬁnal well concentration) or with dopamine (dissolved
in ascorbic acid) at 37 °C for 30min for basal and dose–response studies
or various time points for time-course studies. After aspiration of media
on ice, cells were lysed with 1 ml of solution containing 2.5% (v/v)
perchloric acid, 0.1 mM cAMP, and [14C]-cAMP (6000–8000 dpm), and
incubated for 30 min at 4 °C. Cell lysates from each well was then
aliquoted into a test tube containing 100 μl of 4.2 M KOH and vortexed.
After centrifugation at 400–500 g for 10 min at 4 °C in a Beckman
Coulter Allegra 6R™ centrifuge, the supernatant containing intracellular
[3H]-cAMP formed and [14C]-cAMP was subjected to chromatography
ﬁrstwithDowexAG50W-4X resin (Bio-Rad Laboratories Inc,Mississau-
ga, ON, Canada) and then with alumina N Super I (MP Biomedicals
Canada, Montréal, QC, Canada) as described previously [22]. The
intracellular [3H]-cAMP (CA) amount over the total intracellular
[3H]-adenine uptake (TU) was computed to determine the relativef AC for D1-class receptors. (A, B) Each bar represents the normalized constitutive activity
iplicate. Means ± S.E. of Bmax values (pmol/mg of membrane proteins) were: 2.30 ± 0.24
one-sample t testwhen compared to 100% (wild-type). Differences betweenmock and ST1
sm6.01). (C, D) For each experiment, rawdata of dose–response curveswere ﬁrst analyzed
sion curveﬁtting (GraphPadPrism 6.01). Normalized curveswere generated by expressing
em as a function of logarithmic dopamine concentrations using the same global nonlinear
eriments done in triplicate. Best-ﬁtted pEC50 values (negative logarithm of EC50 in molar
3.9 nM); hD1-ST1, 5.21 ± 0.07 (6216 nM); hD5R, 8.59 ± 0.56 (2.58 nM); and hD5-ST1,
227±4.6 (hD1-ST1), 99.3± 11.6 (hD5R), and 217±15.9 (hD5-ST1). EC50 and Emax values
ceptor parameters using unconstrained and constrained global nonlinear regression curve
0.15 (hD1R), 1.05 ± 0.039 (hD1-ST1), 0.27 ± 0.06 (hD5R), and 0.23 ± 0.04 (hD5-ST1). h,
Fig. 4. The decreased receptor expression for the triple mutant hD1-ST1 is caused by the
Ser65 mutation. (A) SampleWestern blots of hD1R compared with IR1 mutant receptors.
Left panel, immunoblotting studies were performed four times using 40 μg of cell lysate
proteins for each mock and receptor condition. Bmax values (pmol/mg of membrane pro-
teins) of representative example were: 12.3 (hD1R), 2.90 (hD1-ST1), 14.3 (hD1-S56A),
18.0 (hD1-T59V), and 0.580 (hD1-S65A). Right panel,Western blot using 90 μg of cell lysate
proteins for mock and hD1-S65A (Bmax = 0.37 pmol/mg of membrane proteins) revealed
visible 75–80 kDa bands (indicated by arrowhead) that were much more prominent for
hD1-S65A compared to mock. In both left and right panels, hD1-S65A was further distin-
guished by having strong band signals below 50 kDa (indicated by arrowheads). (B) Cell
surface expressions, obtained by ELISA, of IR1 mutant receptors relative to hD1R. Each
bar represents the mean ± S.E. from ﬁve experiments done in triplicate. *, p b 0.05 using
one sample t test when compared to 100% (wild-type). Bmax values (pmol/mg of mem-
brane proteins) expressed as means ± S.E. were: 10.7 ± 0.3 (hD1R), 1.31 ± 0.08 (hD1-
ST1), 13.9 ± 1.3 (hD1-S56A), 12.7± 1.5 (hD1-T59V), and 0.36± 0.05 (hD1-S65A). All ex-
periments (A, B)were performed using 5 μg of transfected receptor or pCMV5 vector DNA
only (Mock). h, human.
Table 3
Saturation and competition binding parameters for hD1R, ST1, and single-point mutant receptors.
pKD and pKI (negative logarithmof KD and KI inmolar units) and Bmax values are expressed asmeans± S.E. from 4–5 separate experiments done in duplicate. The corresponding KD and KI
values in nM are shown in brackets. Binding parameters measured with each ligand were analyzed using two-tailed multiple t test comparisons and the Holm–Sidak correction method
with a critical α= 0.05.
Saturation curves Competition curves
[3H]-SCH23390 (n = 4–5) Dopamine (n = 4–5) Dihydrexidine (n = 4–5)
pKD (KD, nM) Bmax (pmol/mg) pKI (KI, nM)
hD1R 9.32 ± 0.07 (0.48) 13.0 ± 1.8 5.09 ± 0.06 (8171) 6.31 ± 0.05 (490)
hD1-ST1 9.48 ± 0.07 (0.34) 1.57 ± 0.24⁎ 4.82 ± 0.06 (15,230)⁎ 6.27 ± 0.06 (533)
hD1-S56A 9.30 ± 0.04 (0.50) 14.7 ± 1.6# 5.12 ± 0.07 (7667)# 6.33 ± 0.07 (472)
hD1-T59V 9.21 ± 0.09 (0.62) 19.5 ± 2.0# 4.38 ± 0.06 (41,330)⁎,# 5.93 ± 0.07 (1183)⁎,#
hD1-S65A 9.37 ± 0.19 (0.42) 0.41 ± 0.08⁎,# 5.65 ± 0.15 (2234)⁎,# 6.92 ± 0.2 (121)⁎,#
⁎ p b 0.05 when compared to hD1R.
# p b 0.05 when compared to hD1-ST1.
2019B. Zhang et al. / Cellular Signalling 27 (2015) 2014–2025AC activity (expressed as CA/TU × 1000). The functional receptor
expression (Bmax) was obtained from transfected cells (reseeded in
100-mm dishes) in a radioligand binding assay using a concentration
of [3H]-SCH23390 (8–10 nM) in the presence and absence of 10 μM
cis-ﬂupenthixol to determine speciﬁc binding.
2.6. Western blot
Cells were solubilized in 800–1000 μl of radioimmunoprecipitation
assay (RIPA) buffer [23] containing protease inhibitors for at least 1 h.
After centrifugation (15,000 g for 15 min at 4 °C), the supernatant
(solubilized cell components) was aliquoted and protein concentra-
tions were measured using Bio-Rad DC protein assay kit. For each
mock and receptor condition, 40 or 90 μg of protein was loaded in 10%
(v/v) acrylamide gels for SDS-PAGE. Proteins were transferred onto
PVDF membranes using the Trans-Blot SD semidry transfer cell
(Bio-Rad) at 15 V for 18 min. After blocking overnight, membranes
were incubated overnight with either monoclonal rabbit anti-D1R
(ab81296, lot# GR106881-8; Abcam) or polyclonal rabbit anti-D5R
(ab32620, lot # GR2654-2; Abcam) diluted 1:1000 in Tris-buffered
saline and Tween-20 (TBS-T: 20 mM Tris–HCL, pH 7.4; 137 mM
NaCl; 0.2% (v/v) Tween-20) and then incubated for 1 h with secondary
anti-rabbit conjugated to horseradish peroxidase (NA934V; GE
Healthcare) diluted 1:10,000 in TBS-T. Proteins were visualized using
Amersham ECL Prime detection kit (RPN2232; GE Healthcare).
2.7. Enzyme-linked immunosorbent assay (ELISA)
Transfected cells were reseeded in 12-well dishes, which have been
previously treated with 0.01% (w/v) poly-D-lysine (3439-100-01;
Trevigen). On the day of the experiment (48 h post-transfection), media
was aspirated, and cells were ﬁxed with 3.7% (v/v) paraformaldehyde in
PBS for 5 min. For all subsequent steps, 12-well dishes were placed on a
gentle rocker. Each well was washed three times (10 min each) with
PBS containing 0.2% (w/v) BSA. After incubating cells with PBS containing
1% (w/v) BSA for 45 min, media was aspirated, and cells were incubated
for 45 min with mouse anti-HA (32-6700, lot# 1389267; Zymed Labora-
tories) diluted 1:2000 in PBS containing1% (w/v) BSA supplementedwith
NaN3. PBS with 0.2% (w/v) BSA was used to wash the cells three times
(10 min each), followed by a second blocking step with 1% (w/v) BSA in
PBS for 15 min. After media was aspirated, cells were incubated for
45 min with sheep anti-mouse antibody linked to horseradish peroxi-
dase (NA9310V; GE Healthcare) that was diluted 1:1000 in PBS con-
taining 1% (w/v) BSA. Another 10 min washing step with 1% (w/v)
BSA in PBS was included and repeated three times before each well
was given 400 μl o-phenylenediamine dihydrochloride (OPD) solu-
tion (0.4 mg/ml OPD, 0.4 mg/ml urea hydrogen peroxide and
0.05 M phosphate-citrate pH 5.0; SIGMAFAST OPD, P9187). Each
dish was fully covered with aluminum foil and placed on the rocker
for 15 min before 100 μl 3M HCL was added to each well to stop thereaction. Solution from each well was transferred to 96-well plates.
The absorbance at 490 nmwas read using a SpectraMaxM5 (Molecular
Devices).
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GraphPad Prism 6.01 for Windows (GraphPad Software, San Diego,
CA, USA, http://www.graphpad.com)was used for all statistical analysis
and curve ﬁtting. Dissociation constants (KD and KI) and maximal bind-
ing capacity (Bmax) were derived from binding isotherms using a non-
linear regression curve ﬁtting best ﬁtted to one-binding site algorithm.
Raw data (CA / TU × 1000) for dose–response curves were ﬁrst individ-
ually ﬁtted using a four parameter logistic equation under a shared Hill
slope. Averaged curves with best ﬁtted parameters (EC50 and Emax)
were constructed by expressing each point from individual curves as a
percentage relative to Emax of wild-type condition (set at 100%) and
then pooling them together in correspondence to the dose. Curves for
time course studies were ﬁtted to an exponential cAMP accumulation
equation Y= Ymax · (1− e−kX), where Y is the amount of intracellular
cAMP formed at each time point, k is the measured rate constant (kobs)
for the formation of cAMP over time (X) with min−1 units, and Ymax is
the maximal amount of intracellular cAMP that can be produced at
long time. Comparisons of best-ﬁtted parameters between experimen-
tal conditions were done through unconstrained, shared, and
constrained global curve ﬁtting. Statistical treatment of ligand binding
(KD, Bmax, KI) and receptor activation (EC50, Emax, kobs, Ymax) parameters
were done as indicated in text. In all statistical analysis, detectableFig. 5. The changes in downstream AC activation for the triple mutant hD1-ST1 are primarily in
receptors using 5 μg of transfected receptor or pCMV5 vector DNA only (Mock). Each bar repres
S.E. from three to four experiments done in triplicate. Bmax values (pmol/mg of membrane pro
S56A), 18.5 ± 1.7 (hD1-T59V), and 0.33 ± 0.04 (hD1-S65A). *, p b 0.05 using one-sample t t
T59V, and hD1-S65A were not statistically detectable (p N 0.05) using multiple t test compari
curves of dopamine-mediated AC activation in cells expressing hD1R and IR1mutant receptors.
as the percentage of Emax obtained with hD1R as discussed in legend of Fig. 3. Best-ﬁtted pEC50
EC50 (in brackets) were: hD1R, 7.83 ± 0.38 (14.7 nM); hD1-ST1, 5.40 ± 0.10 (4010 nM)*; hD1-S
0.13 (107 nM)*,#. Best-ﬁtted values of Emax (%)± approximate S.E. were 99.5± 11.0 (hD1R), 37
(hD1-S65A)*,#. Statistical differences in EC50 and Emax values of IR1mutantswere assessed relati
constrained global nonlinear regression curve ﬁtting approach. *, p b 0.05 when compared to hD
(expressed as means ± S.E.) were: 1.35 ± 0.18 (hD1R), 1.75 ± 0.24 (hD1-ST1), 1.46 ± 0.33 (h
values as in (B) and the addition of “hD1R-low” whose Bmax was 0.36 ± 0.13 (in pmol/mg of m
pressions of IR1 mutant receptors were not found to be statistically different from hD1R usin
from four to six experiments done in triplicate. h, human.differences in numerical results were deemed statistically signiﬁcant
if p b 0.05.
3. Results
3.1. IR1 promotes receptor expression and agonist afﬁnity for D1-class
receptors
As a screening study, we initially created two mutants, hD1-ST1 and
hD5-ST1, which replaced all Ser/Thr residues of IR1 to Ala/Val, respec-
tively. We used 5 μg of transfected receptor DNA for all saturation
studies because it yields the maximum Bmax for hD1R and hD5R in our
transfection paradigm with HEK293 cells [22]. Saturation studies
demonstrated that both ST1 mutants were able to bind to the selective
D1-class ligand [3H]-SCH23390 with high afﬁnity and statistically
similar KD values relative to their parent receptor (Table 2). The Bmax
value was signiﬁcantly lowered in both ST1 mutants relative to their
wild-types, with hD5-ST1 displaying a larger decrease compared to
hD1-ST1 (95% vs. 85%). Due to the cell-permeability of [3H]-SCH23390
and use of crude receptor membrane preparations, the Bmax value is
predicted to measure the total amount of functional receptors (i.e.
binding-competent receptors), incorporating those on the cell surface
and those inside the cell (e.g. vesicles, Golgi compartments). To furtherﬂuenced by Thr59 and Ser65 mutations. (A) Constitutive activity of hD1R and IR1 mutant
ents the normalized constitutive activity relative to wild-type that is expressed asmean±
teins) in means ± S.E. were: 13.0 ± 1.0 (hD1R), 1.41 ± 0.16 (hD1-ST1), 12.2 ± 0.7 (hD1-
est when compared to 100% (wild-type). Differences between mock and hD1-ST1, hD1-
sons and the Holm–Sidak correction method (GraphPad Prism 6.01). (B) Dose–response
Each point is themean± S.E. from three to four experiments done in triplicate and plotted
values (negative logarithm of EC50 in molar units) ± approximate S.E. and corresponding
56A, 8.15± 0.38 (7.17 nM)*,#; hD1-T59V, 5.32± 0.39 (4770 nM)*; and hD1-S65A, 6.97±
0±10.5 (hD1-ST1)*, 95.5± 10.2 (hD1-S56A)#, 92.2± 9.84 (hD1-T59V)*,#, and 313± 11.1
ve to their correspondingwild-type receptor and ST1 parameters using unconstrained and
1R; #, p b 0.05 when compared to hD1-ST1. Bmax values in pmol/mg of membrane proteins
D1-S56A), 1.37 ± 0.17 (hD1-T59V), and 0.26 ± 0.09 (hD1-S65A). (C) Under similar Bmax
embrane proteins expressed as mean ± S.E.) to match that of hD1-S65A, cell surface ex-
g one-sample t test compared to 100% (wild-type). Each bar represents the mean ± S.E.
2021B. Zhang et al. / Cellular Signalling 27 (2015) 2014–2025understand the underlying reasons for decreased Bmax values of ST1
mutants, we examined the receptor protein expression and cell surface
localization using Western blots and ELISA.
Using 5 μg of transfected untagged receptor DNA, we observed a
major broad 75–80 kDa band of hD1R to be greatly diminished in the
hD1-ST1. A similar band size has been found with rat D1R in striatal
preparations and HEK293 cells [23], and has also been reported to rep-
resent a glycosylated D1R in the monkey brain [24] (predicted molecu-
lar weight for hD1R is 49 kDa). Furthermore, a 60–65 kDa band present
in hD1Rwas almost undetectable in hD1-ST1 during short ﬁlm exposure
periods (Fig. 2A). These immunoblot changes of hD1-ST1 were reﬂected
by its reduced cell surface expression (a 59% decrease relative to wild-
type) obtained with ELISA on HA-tagged receptor constructs (Fig. 2C).
In comparison to the immunoblot proﬁle of hD5R, the hD5-ST1 lacked
a strong band signal between 60 and 65 kDa. Because this difference
was correlated with the diminished cell surface expression of HA-
tagged hD5-ST1 (a 54% decrease relative to wild-type), this band could
possibly represent the mature glycosylated form of hD5R (predicted
molecular weight for hD5R is 53 kDa) (Fig. 2B and D). The appearance
of a 130 kDa band for hD5Rwas not surprising as highmolecular weight
bands (N100 kDa) have been previously observed in rat and monkey
brains [25,26]. This band could possibly represent a dimeric form of
hD5R. Interestingly, we also detected an equivalent 130 kDa band for
hD5-ST1. Whether these 130 kDa molecular species among hD5R and
hD5-ST1 have different cellular localizations remains to be tested in
future studies.
To assess any changes by the triple mutations towards receptor
binding function, competition studies were performed with a series ofFig. 6. Time-course of dopamine-mediated stimulation of AC for hD1R andmutant receptors of IR
intracellular cAMPproduced that is plotted against stimulation time intervals of 1min, 3min, 5m
cAMPaccumulation equation Y= Ymax · (1− e−kX) as discussed in Section 2.8. Bmax values (pm
0.1 (hD1-ST1), 1.40± 0.2 (hD1-S56A), 1.36± 0.2 (hD1-T59V), and 0.23± 0.01 (hD1-S65A). Fin
for hD1-ST1 and hD1-T59V. (B, C) Bar graphs plotting the best-ﬁtted values ± approximate S.E
strained and constrained global nonlinear regression curve ﬁtting approach. *, p b 0.05 when cD1-class agonists, dopamine and dihydrexidine; and reported inverse
agonists, thioridazine and thiothixene [2].Mutating IR1 Ser/Thr residues
brought upon a 2- and 4-fold loss in dopamine afﬁnity for hD1R and
hD5R, respectively. The hD5-ST1 displayed a 4-fold loss of afﬁnity for
dihydrexidine; meanwhile, hD1-ST1's afﬁnity remained statistically
unchanged in relation to wild-type (Table 2). Afﬁnities for thioridazine
and thiothixene remained relatively unchanged among ST1 mutants in
comparison to wild-type, with only hD1-ST1 exhibiting a small but
statistically signiﬁcant increased afﬁnity for thiothixene.
3.2. Ser/Thr residues of IR1 regulate AC activation by D1-class receptors
Both hD1R and hD5R are able to activate AC in an agonist-
independent manner, the latter being more constitutively active. Their
degrees of constitutive activity have been shown to be directly propor-
tional to their receptor expressions [27]. In the case for both ST1
mutants, these constitutive activities were abolished to levels of
mock-transfected cells, indicating that IR1 Ser and Thr residues play a
critical role in facilitating agonist-independent G protein coupling
(Fig. 3A and B).
To assess agonist-mediated activation of AC, cells were
transfected with either mutant or parent receptor at matched
expression levels (~1 pmol/mg for hD1R and hD1-ST1; ~0.30 pmol/mg
for hD5R and hD5-ST1) and then stimulated with dopamine in a dose-
dependent manner. The 10-fold difference between EC50 values of hD1R
and hD5R (see caption of Fig. 3) is in agreement with previous studies
[2,22]. For mutant receptors, both hD1-ST1 and hD5-ST1 displayed a pro-
nounced rightward shift in EC50 compared to wild-type (260-fold for1. (A) Eachpoint represents themean from four experiments (done in triplicate) depicting
in, 10min, 20min, and 30min. CurveswereﬁttedwithGraphPadPrism to an exponential
ol/mg ofmembrane proteins) expressed asmeans±S.E.were: 1.23±0.07 (hD1R), 1.04±
al dopamine concentrationswere 10−5 M for hD1R, hD1-S56A, and hD1-S65A; and 10−2 M
. of kobs and Ymax. Statistical comparisons of kobs and Ymax values were done using uncon-
ompared to hD1R; #, p b 0.05 when compared to hD1-ST1.
2022 B. Zhang et al. / Cellular Signalling 27 (2015) 2014–2025hD1-ST1 and 56-fold for hD5-ST1) (Fig. 3C and D). This large potency
change cannot be fully described by their 2- or 4-fold loss in dopamine af-
ﬁnity and therefore implies that agonist-dependent G protein coupling
was impaired. Interestingly, despite the warranted uncoupling from the
G protein, both ST1 mutants were able to increase their dopamine-
mediatedmaximal activation (Emax) of AC bymore than 2-fold compared
to wild-type (Fig. 3C and D). Taken together, our screening study implies
that IR1 Ser/Thr residues of hD1R and hD5R share similar roles in modu-
lating dopamine afﬁnity, constitutive activation, and agonist-induced
AC stimulation.3.3. The hD1-ST1 functional phenotype is primarily inﬂuenced bymutations
at Thr59 (Thr2.39) and Ser65 (Ser2.45)
Next, we sought out to pinpoint which individual Ser/Thr mutations
of IR1 underlay the receptor properties of the ST1 mutants using hD1R
as the prototypical GPCR. Three point mutants within IR1 of hD1R
were constructed and denoted as hD1-S56A, hD1-T59V, and hD1-S65A.
All three retained high afﬁnities for SCH23390 that were comparable
to wild-type. The diminished expression of hD1-ST1was solely attribut-
ed to mutating Ser65 to Ala (Table 3). This decrease was offset by the
other two point mutants whose Bmax was either equivalent or higher
than wild-type and therefore played a role in partially elevating
the hD1-ST1 expression above the hD1-S65A. Both the hD1-S56A and
hD1-T59V mutants displayed similar immunoblot proﬁles and cell sur-
face expressions as wild-type (Fig. 4A and B). On the other hand, the
75–80 kDa and 60–65 kDa bands found in hD1R could not be discerned
in hD1-S65A during short ﬁlm exposure times using 40 μg of cell lysate.
However, by increasing the amount of loaded protein to 90 μg for both
mock and hD1-S65A, the hD1-S65A exhibited a 75–80 kDa band that
was noticeably greater in intensity compared to the mock (Fig. 4A).
Interestingly, the hD1-S65A presented stronger immunostaining
below 50 kDa compared to other mutants and hD1R (Fig. 4A). Since
the expected molecular weight for hD1R is 49 kDa, these bands could
possibly represent immature and/or degraded forms of hD1-S65A. In
accordance with its diminished Bmax value, cell surface expression forTable 4
Potential hydrogen bonds of Thr2.39 andSer2.45 in various Family AGPCRs. For solved structure
monomerswas included. Atoms of side chainswere speciﬁed following atom labels in the PDB f
tiﬁed using HBPLUS [50]. N/A, denotes Thr2.39 or Ser2.45 was not found to be conserved. –, d
Thr2.39 or Ser2.45.
Solved GPCR structure PDB accession
code (reference)
Thr2.39
OG1 contacts
Donor
(Å) fro
Antagonist or inverse agonist bound to R
Adenosine A2A receptor with ZM241385 3EML [51] Asp3.49 OD2 2.62 (
β1-adrenoceptor with cyanopindolol 2VT4 [52] Asp3.49 OD2 3.43 (
β2-adrenoceptor with carazolol 2RH1 [53] – –
Dopamine D3 receptor with eticlopride 3PBL [54] Asp3.49 OD2 2.78 (
Arg3.50 NH1 2.70 (
Histamine H1 receptor with doxepin 3RZE [55] N/A N/A
Muscarinic M2 receptor with
3-quinuclidinyl-benzilate
3UON [56] N/A N/A
Muscarinic M3 receptor with tiotropium 4DAJ [57] N/A N/A
δ opioid receptor with naltrindole 4N6H [32] Arg3.50 NH2 3.17 (
κ opioid receptor with JDTic 4DJH [58] Arg3.50 NH1 3.20 (
μ opioid receptor with β-funaltrexamine 4DKL [59] – –
Agonist bound to intermediate or full R*
Adenosine A2A receptor with NECA 2YDV [60] Tyr3.60 OG1 2.71 (
β2-adrenoceptor with BI-167 107 and in
complex with Gs
3SN6 [33] Tyr3.60 OG1 2.69 (
Muscarinic M2 receptor with iperoxo 4MQS [61] N/A N/A
5-HT1B receptor with ergotamine 4IAR [62] N/A N/A
5-HT2B receptor with ergotamine 4IB4 [63] – –hD1-S65A was lower than hD1R and hD1-ST1 (a 79% decrease relative
to wild-type) (Fig. 4B).
Although hD1-ST1was previously shown to have a 2-fold loss in do-
pamine afﬁnity, more pronounced effects were found in single point
mutants. The hD1-T59V exhibited a 5-fold decrease, while hD1-S65A
demonstrated a 4-fold increase in dopamine afﬁnity (Table 3). It
appeared that the T59V mutation had a more prevalent effect on dopa-
mine binding compared to the S65Amutation because its effect (lower-
ing afﬁnity)was partiallymanifested in thehD1-ST1 bindingphenotype.
Competition studies with dihydrexidine revealed that the T59V
mutation lowered afﬁnity by 2-fold, while the S65Amutation increased
afﬁnity by 4-fold in comparison to wild-type (Table 3). Once again, the
T59V exerted the dominant effect amidst the interplay of the two be-
cause hD1-ST1's afﬁnity for dihydrexidine was statistically unchanged
from hD1R. It should also be noted that mutating Ser56 to Ala did not
statistically alter hD1R's afﬁnity for dopamine and dihydrexidine.
The impact on hD1R-triggered AC activity by these IR1 point muta-
tions and how they could match to the hD1-ST1 was then assessed.
The hD1-T59V recapitulated the abolished basal activity of hD1-ST1
even when its Bmax appeared to be greater than hD1R (Fig. 5A). In con-
trast, the hD1-S56Amutation induced a small but statistically signiﬁcant
increase in basal activity relative to hD1R at comparable Bmax levels.
Whether hD1-S65A mutation caused a change in constitutive activity
is currently unknown because the basal activity of hD1R could not be
detected at low expression levels matching hD1-S65A (~0.3 pmol/mg
of membrane proteins). Upon stimulation with dopamine in a dose-
dependent manner, the hD1-T59V exhibited the large rightward EC50
shift (over 300-fold but statistically indistinguishable from hD1-ST1
relative to hD1R), while the hD1-S65A mutation produced the elevated
Emax of AC characteristic of hD1-ST1 (Fig. 5B). Although the hD1-S56A
mutation produced wild-type levels in Emax of AC, it also created a
2-fold increase in dopamine potency (leftward EC50 shift).
To demonstrate the increased Emax of AC for hD1-ST1 and hD1-S65A
were not due to differences in cell surface expression from hD1R, we
conducted ELISA on hD1R and IR1 mutants expressed at Bmax values
analogous to Fig. 5B. When Bmax values were matched to approxi-
mately 1 pmol/mg of membrane proteins, the hD1-ST1, hD1-S56A,swithmore than onemonomer, the corresponding letter assignment (A, B, C, D, etc.) of the
ormat. Hydrogen donor and acceptor atoms and their donor–acceptor distanceswere iden-
enotes no interacting residue or side-chain side-chain interaction was found with either
–acceptor distance
m speciﬁc monomer
Ser2.45 OG
contacts
Donor–acceptor distance
(Å) from speciﬁc monomer
A) Trp4.50 NE1 3.09 (A)
A); 3.43 (D) Trp4.50 NE1 2.97 (A); 3.11 (B); 3.13 (C); 2.97 (D)
Trp4.50 NE1 2.97 (A)
A); 2.83 (B) Asn3.42 OD1/ND2 2.72/2.84 (A); 3.21/3.16 (B)
B) Trp4.50 NE1 2.86 (B)
Ser3.42 OG 2.66 (A)
Trp4.50 NE1 2.84 (A)
Asn3.42 OD1 2.93 (A)
Trp4.50 NE1 2.84 (A)
Asn3.42 ND2/OD1 2.63 (A)/2.68 (B)
Trp4.50 NE1 3.30 (B)
A) N/A N/A
B) N/A N/A
N/A N/A
A) – –
R) Trp4.50 NE1 3.08 (R)
Asn3.42 ND2 3.10 (A)
Trp4.50 NE1 3.05 (A)
– –
His3.42 NE2 2.94 (A)
Trp4.50 NE1 2.86 (A)
2023B. Zhang et al. / Cellular Signalling 27 (2015) 2014–2025and hD1-T59V all showed resembling levels of cell surface expression
relative to hD1R (Fig. 5C). For the low Bmax of hD1-S65A (~0.3 pmol/mg
of membrane proteins), we titrated Bmax of hD1R to matched levels and
did not ﬁnd any signiﬁcant differences in cell surface expression be-
tween the two (Fig. 5C). Therefore, these results further validate our as-
sumption that the Bmax value, particularly when describing wild-type
and IR1 mutant receptors, is correlated with cell surface expression.
Furthermore, to examine the kinetics of the increased Emax of AC for
hD1-ST1 and hD1-S65A during the 30 min stimulation period, we
performed time-course studies (Fig. 6). We observed the total cAMP
accumulated after 1 min of dopamine stimulation for hD1-ST1 and
hD1-S65A were already 2-fold higher than hD1R, and this differential
gap increased during longer periods of dopamine treatment. Despite
having an elevated plateau (Ymax), the observed rate constant (kobs)
for hD1-ST1 and hD1-S65A were not statistically different from hD1R
and the other two point mutant receptors (Fig. 6). In other words,
hD1-ST1 and hD1-S65A were able to reach their maximal signaling re-
sponse at the same time as wild-type; however, their mutations en-
abled them to have greater cAMP responses that began quickly after
agonist stimulation and persisted upon prolonged agonist stimulation.
4. Discussion
In our screening studies, we found mutating all Ser/Thr residues of
IR1 for both hD1R and hD5R caused an ablated basal activity, decreasedFig. 7.Molecular interactions of Thr2.39 and Ser2.45 in solved GPCR structures. (A) In the adeno
hydrogen bondswith Asp3.49 of the highly conserved DRYmotif. In addition, Asp3.49 forms a s
of the β2-adrenoceptor (3SN6) hydrogen bonds with Tyr3.60 of IL2 and consequently helps po
Arg380) on theGαs subunit (shown in red). Asp3.49 also interacts with Tyr3.60. Note that in (A,
IL1. (C) Ser2.45, by the juncture of IL1/TM2, participates in a hydrogen bond network with Trp
ﬁgures (A–C) were made using Pymol. Membrane boundaries, denoted by blue plus symbols,
tracellular loop.dopamine afﬁnity and potency, and an increased Emax of AC. These
mutations, according to the extended ternary complex model [3], shift
the thermodynamic equilibrium closer towards an inactive R state and
also suggest that IR1 Ser/Thr residues function in a similar manner
among D1-class receptors. Furthermore, the decreased Bmax values, to-
gether with immunoblot and ELISA data, suggest that there is a small
population of D1-class ST1 receptors that bypass the ER quality control
mechanisms [28] to become mature and functional receptors at the
cell surface. This corresponds to previously mentioned studies in the in-
troduction, indicating the role of IL1 in receptor trafﬁcking to the plasma
membrane. IR1 mutant receptors may also be subjected to a quality
control at the plasma membrane that is responsible for their retrieval
to a degradation pathway [29].
In regard to the agonist binding changeswe observed among D1-class
IR1 mutant receptors, they are likely to be indirect. For instance, the
decreased afﬁnities for dopamine exhibited by ST1 mutant receptors
could be caused by their increased tendency to be uncoupled (i.e.
conﬁned in an inactive R state) compared to wild-type receptors. It is
also possible that upon replacing hydrophilic (polar) residues (Ser/Thr)
with hydrophobic residues (Ala/Val), the IR1 regions of hD1R and hD5R
undergo topological changes. These changes may translate into three-
dimensional rearrangements of TM1 and TM2, which culminate into
the altered agonist binding afﬁnities observed for our IR1 mutant recep-
tors. Indeed, previous studies have indicated that TM2 dictates the
subtype-speciﬁc agonist afﬁnities between β1- and β2-adrenoceptorssine A2A receptor bound to ZM241385 (3EML), representative of a R state receptor, Thr2.39
alt bridgewith Arg3.50 and hydrogen bondswith Tyr3.60 of IL2. (B) Thr2.39 in the R* state
sition Phe3.58 of IL2 into the hydrophobic pocket (created by His41, Val217, Phe376, and
B), TM4 has beenmade transparent for illustrative purposes to present the full structure of
4.50 and Asn3.42, as shown in the dopamine D3 receptor bound to eticlopride (3PBL). All
were predicted using the database from Orientation of Proteins in Membranes [49]. IL, in-
2024 B. Zhang et al. / Cellular Signalling 27 (2015) 2014–2025[30]; as well, residues in TM2 and TM7 are postulated to form a binding
pocket [31]. Furthermore, TM2 harbors a conserved Asp residue (Asp
2.50, Fig. 1), which plays a role in the allosteric modulation of agonist
binding of several Family A GPCRs (e.g. β2-adrenoceptor, D1 and D2
dopaminergic receptors) by monovalent cations [32]. Interestingly,
unlike the afﬁnity losses detected with hD5-ST1 for both dopamine and
dihydrexidine (both 4-fold), hD1-ST1 did not display any afﬁnity change
for dihydrexidine relative to wild-type. Consequently, the ability of hD1R
to be selective for dihydrexidine over dopamine was enhanced in the
hD1-ST1, which was not the case between hD5R and hD5-ST1. Although
a combinatorial effect of the mutations is likely contributing to the func-
tional phenotype of hD1-ST1 and hD5-ST1, the binding results suggest a
potential role of IR1 in shaping the intricate differenceswithin the agonist
binding pocket among D1-class receptors.
Although the ablated basal activity and large rightward EC50 shift
strongly indicate a role for IR1 in G protein coupling among D1-class
receptors, IR1 was not shown to have any molecular contacts with the
G protein in the β2-adrenoceptor Gs complex—currently, the solely
available crystallized GPCR bound to a G protein heterotrimer [33].
One possible explanation is that IR1 helps other residues interact with
the G protein, and this will be discussed further later on. On the other
hand, until more crystallized examples of GPCRs bound to full G
proteins are presented in the future, IR1 may indeed, as in the case for
D1-class receptors, have direct bindingwith the G protein. Interestingly,
our results show despite both ST1 mutants demonstrating between
2- to 4-fold losses in dopamine afﬁnity, the hD1-ST1 exhibited a
260-fold rightward EC50 shift, which was much more pronounced
compared to the 56-fold experienced by the hD5-ST1. This differential
gap illustrates that although IR1 for both subtypes may have similar
functions, they are utilized differently, resulting in the distinct down-
stream signal transduction responses.
Concomitant with a decreased potency for dopamine was the over
2-fold elevation in Emax of AC for both ST1mutants. ELISA assays indicat-
ed this was not caused by unequal cell surface expression. Based on
time-course studies, we believe ST1 mutants may have a prolonged
agonist-induced cAMP response. Classically, receptor phosphorylation
and/or β-arrestin binding comprise the regulatory machinery responsi-
ble for signal termination through its targeting of intracellular domains
on the receptor. To our knowledge, only a few studies have indicated the
involvement of IL1. For instance, Ser/Thr mutations in IL1 of the
follitropin receptor reduced receptor phosphorylation, association
with β-arrestin-2, and internalization upon treatment with follitropin
[34,35]. In another case, Asn73 within IL1 of rhodopsin was determined
to be important for arrestin binding [36,37]. Alternatively, following re-
cruitment to clathrin coated pits by β-arrestin-2, the μ opioid receptor
was demonstrated to be ubiquitinated at IL1 by Smurf2, and this could
serve as a checkpoint to allow cleavage of the endocytic vesicle [38]. It
is also plausible for IR1 to regulate the Emax of AC for D1-class receptors
beyond the plasmamembrane as agonist-induced cAMP responses have
been shown to occur from endosomes [39]. We have not detected
differences among kobs, and these ﬁndings potentially underscore a
minor role of IR1 Ser/Thr in agonist-induced desensitization. Follow-
up studies are underway in our laboratory to directly evaluate the
possibilities involving changes in desensitization, endocytosis, and
signaling within an internalized active complex.
In our single mutagenesis studies, we found mutating Ser56 to Ala
did not bring any major changes towards hD1R function. This coincides
with a previous study (using Chinese hamster ovarian cells) whereby
mutating Ser56 to Leu did not alter ligand binding or G protein coupling
to hD1R [40]. More importantly, our studies revealed the functional
alterations present in hD1-ST1 were the combinatorial effect from mu-
tating two residues: Th59 and Ser65. Because Thr59 and Ser65 are
also conserved in hD5R, we believe these two residues will have parallel
functions and be responsible for the pleitropic effects of the hD5-ST1.
As previously mentioned, Thr59 and Ser65 are also well-conserved
among other Family A GPCRs (Fig. 1B). Because the crystal structuresof these receptors have already been solved (Table 4), a three-
dimensional context can be provided to highlight the functional
importance of Thr59 and Ser65 found in hD1R. As shown in Table 4,
for the conserved Thr2.39 (Ballesteros–Weinstein nomenclature;
equivalent to Thr59 in hD1R), its hydroxyl side chain is in proximity to
hydrogen bond with the highly conserved DRY motif (either Asp3.49
or Arg3.50)within theR state conformations of various receptors: aden-
osine A2A (3EML), β1-adrenergic (2VT4), dopamine D3 (3PBL), δ opioid
(4N6H), and κ opioid (4DJH) (see Fig. 7A for example). Thr2.39 is also
indirectly linked to Arg3.50 through a sulfate ion bridge in the R state
conformation of the β2-adrenoceptor (2RH1). Upon transitioning to a
R* state, as shown by the A2A receptor (2YDV) and β2-adrenoceptor
(3SN6), Thr2.39 breaks free from the DRY motif, and similar to
Asp3.49, interacts with Tyr3.60 near the center of IL2. This positions
IL2 to contact Gαs; for example, the insertion of Phe3.58 into a hydro-
phobic pocket of Gαs [33] (Fig. 7B). Assuming a similarmolecular topog-
raphy is present in hD1R (Phe3.58 and Tyr3.60 are conserved in human
D1-class receptors), we suggest upon mutating Thr2.39 to Ala in hD1R,
Tyr3.60 of IL2 loses support from Thr2.39. Consequently, this alters
the R* conformation of IL2 and prevents the proper insertion of
Phe3.58 into the hydrophobic pocket of Gαs. This can explain the loss
in basal activity and over 300-fold decrease in dopamine potency seen
with our hD1-T59V mutant receptor. Indeed, previous studies have
demonstrated, without a bulky hydrophobic residue at position 3.58,
agonist-induced signaling becomes greatly impaired [41–43].
In almost all theGPCRs listed in Table 4, Ser2.45 (equivalent to Ser65
in hD1R) can form hydrogen bondswith Trp4.50 and sometimes in con-
junction with a polar residue at position 3.42 (Ser/His/Asn), regardless
of R or R* states (see Fig. 7C for example). Furthermore, for the opioid
receptors listed in Table 4, Ser2.45 is replaced by Asn2.45, which partic-
ipates in the same hydrogen bonding network with Trp4.50 and
Thr3.42. Our studies with hD1-S65A indicate that breaking these poten-
tially conserved interactions between IR1 and TM3/TM4 for hD1R
resulted in a robust increase in Emax of AC. Previous studies have
shown that the highly conserved Trp4.50 can be important for the
ligand binding of the cannabinoid CB2 receptor [44], dopamine D2
receptor [45], and the adenosine A1 receptor [46]. Moreover, Trp4.50
of the β2-adrenoceptor has also been shown to interact with cholesterol
via CH-π hydrogen bonding [47]. To our knowledge, the contribution of
Trp4.50 towards ligand-induced signaling is unclear. Likewise, the role
of a polar residue at 3.42 (Thr/Ser/His/Asn) in dictating GPCR function
has not been explored.5. Conclusion
Overall, this study has demonstrated for the ﬁrst time signiﬁcant
contributions of IR1 in regulating agonist binding, constitutive
activation, and agonist-induced activation (including Emax of AC) for
D1-class receptors. Furthermore, our data suggest that IR1 can contrib-
ute to receptor trafﬁcking. The pleiotropic functions of IR1 was found
to be conferred by two nearby residues, Thr59 and Ser65 of hD1R, that
may participate in molecular interactions with conserved residues of
IL2, TM3, and TM4 in the same pattern found in many crystallized
GPCRs. Studies in our laboratory are presently underway to verify the
molecular interactions of Ser2.45 with Trp4.50/Asn3.42 in hD1R and to
also identify the speciﬁc cellular mechanism(s) underlying the in-
creased Emax of AC for hD1-ST1 and hD1-S65A. Our mutational analysis
of Thr2.39 and Ser2.45 thus highlights the unappreciated role of IL1
and its transition into TM2, which needs to be accounted for in our
current canonical models of GPCR signaling.Conﬂict of interest
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